arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

INTENSITY THERAPEUTICS, INC.

INTS
$4.08 ▲ +0.01 (+0.25%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
19 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTENSITY THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -26.4%
FCF / Share $-0.86
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.43M
↑ +27.3%
FCF / Share Free cash flow per share
$-0.86
↓ -20.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters